CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02663297
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:48.324727+00:00
Published At: 2025-05-15T00:00:00+00:00
Record Updated At: 2025-05-15
Results Posted At: 2025-05-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hodgkin Disease", "Lymphoma", "Lymphoma, Non-Hodgkin", "Immune System Diseases", "Immunoproliferative Disorders", "Lymphatic Diseases", "Lymphoproliferative Disorders", "Neoplasms", "Neoplasms by Histologic Type"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-05-15"
protocolSection.identificationModule.nctId: "NCT02663297"
protocolSection.identificationModule.officialTitle: "Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-05-15"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.